Oxford Biomedica has signed a new Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s company, Juno Therapeutics to use Oxford Biomedica’s LentiVector platform for its application in CAR-T and TCR-T programmes in oncology and other indications.
This deal additionally puts in place a five year Clinical Supply Agreement, which may be extended further, said Oxfor Biomedica in its press release.
Under the terms of the LSA, Oxford Biomedica will get $10 million upfront and potentially up to $86 million upon certain milestones.
Oxford Biomedica could also get up to $131 million in sales-based milestone payments and an undisclosed royalty on the net sales of products sold by Juno Therapeutics with using the LentiVector platform. Oxford Biomedica also said it would receive payments from process development and scale-up projects as well as relating to the GMP manufacture of lentiviral vectors for use in clinical trials
As part of the LSA, Juno Therapeutics will have access to Oxford Biomedica’s new 7,800 m2 commercial manufacturing centre OxBox, in Oxford, UK. Oxford Biomedica said it is already working on four undisclosed active projects, with Juno able to initiate additional projects in the future.
John Dawson, Chief Executive Officer of Oxford Biomedica, said: “Juno Therapeutics, a Bristol-Myers Squibb company, is a recognized leader with an innovative pipeline in the CAR-T and TCR-T field and we are delighted to sign this new agreement with them. This new relationship with a long-established leader in the CAR-T field, underlines the value of Oxford Biomedica’s LentiVector® platform for leading companies. By offering world-leading lentiviral vector technologies and proven clinical and commercial manufacturing capabilities, we are able to offer our partners and customers a unique suite of capabilities not found elsewhere in the industry.
“This is the second company that has committed to working with us in our new OxBox facility, which we expect to be producing GMP vector by the end of the first half of 2020. Today’s announcement further validates our decision taken in 2018 to invest in and scale up our GMP manufacturing facilities for clinical and commercial viral vector manufacture to support both existing and new partners and customers as well as the expected demand from industry.”